CIRIUM
24.1.2023 09:01:33 CET | Business Wire | Press release
The new Cirium Fleet Forecast reveals demand for approximately 44,500 new aircraft globally over the next two decades, worth US$2.9 trillion.
The forecast published by Ascend by Cirium, the consultancy arm of aviation analytics firm Cirium, is an independent outlook of the global passenger and freighter market for the next 20 years.
It reaffirms an encouraging long-term projection for the aviation industry and its recovery from the Covid-19 pandemic, predicting that 20-year aircraft deliveries will be 1% lower globally than predicted a year ago.
This comes despite Russia’s invasion of Ukraine, travel restrictions in China, and rising energy costs all emerging as influential factors during 2022.
The aviation industry’s recovery from the Covid-19 crisis in early 2020, has progressed significantly if unevenly across regions. Global aviation activity is predicted to reach 2019 levels in October.
Rob Morris, Ascend by Cirium’s Global Head of Consultancy, said: “The new Cirium Fleet Forecast shows a positive long-term outlook for aviation. The industry is undergoing structural changes but remains on course to return to traditional growth paths by 2025.”
“The global passenger fleet will be required to increase by around 22,000 aircraft to service passenger traffic, which we predict to grow 3.6% annually to reach 47,700 aircraft by the end of 2041.
“These new aircraft will be required to meet demand for air travel, but also to replace less efficient, older-generation types.”
Asia will account for over 40% of new deliveries
Asia-Pacific remains the key growth region for new deliveries, driven by China. The country is forecast to have the highest annual passenger traffic growth rate at over 6% and account for 19% of deliveries in 2041, ahead of all other Asia-Pacific countries, with a combined share of 22%.
North American and European airlines are projected to account for 21% and 17% of deliveries respectively. Middle East airlines will take 7% of deliveries, accounting for 14% in value terms due to the rich mix of higher value twin-aisle deliveries.
In the forecast, Russian capacity and traffic are assumed to decline in the near term. Combined with the complete cessation of Ukrainian civil aviation activity, Russia/CIS traffic is then forecast to stabilize at 70% of 2019 levels in 2024.
Demand for single-aisles will drive fleet growth
At the end of November 2022, the single-aisle fleet was within 2% of 2019 levels, but twin-aisle aircraft numbers were still down by 20%. The single-aisle fleet will grow faster by 3.7% annually, against 3.2% for twin-aisles as the recovery of long-haul traffic continues to lag. The regional aircraft fleet will rise more modestly, by 1.1% a year, with the turboprop fleet set to grow at a faster rate within the regional sector.
Forecast traffic growth over the long term will require the global passenger fleet to increase by around 22,000 aircraft, which equates to a 3.1% annual growth rate, taking the inventory to some 47,700 aircraft at the end of 2041.
The in-service passenger fleet is not forecast to return to 2019 levels until mid-2023, thus effectively losing up to four years of ‘normal’ fleet growth.
Airbus and Boeing will remain the two largest commercial aircraft OEMs, delivering an estimated 80% of aircraft between them and 88% by value through 2041. However, there is US$360 billion of demand for other OEMs or new programs.
The pressures to replace older, less-efficient types will increase
Close to 88% of the current passenger fleet is forecast to be retired from passenger service during the next 20 years. Freighters have longer useful economic lives, so approximately 70% of the current fleet will be retired by 2041.
Overall, there will be some 19,000 retirements from the end-2021 passenger fleet, plus a further 2,500 aircraft that leave the passenger fleet via cargo conversion.
As pressure to switch to more environmentally friendly aircraft grows, replacing less efficient older-generation types will be an increasingly important element of fleet planning. The Covid-19 crisis has seen relatively young aircraft being phased out, while those of older vintages may remain in storage until eventual scrapping.
The freighter boom continues, but may not persist
Freight capacity (available tonne kilometres or ATKs) is forecast to grow annually at 3.0% and traffic (FTKs) at 3.7%, relative to 2019. The forecast predicts the supply of some 3,560 freighter aircraft over the next 20 years, including 1,060 new builds (30%) worth US$130 billion, and 2,480 conversions of passenger aircraft (70%).
This is a similar volume and profile to that predicted in the previous forecast, reflecting the continued near-term boom in conversions triggered by the air-cargo market dynamics of the Covid-19 pandemic, including a short-term drop in passenger belly capacity, e-commerce growth and rising feedstock availability. Although the current conversion boom may not persist, it is enabling the replacement of older, less efficient aircraft.
To download an executive summary of the Cirium Fleet Forecast, [click here]
About Cirium
Cirium brings together powerful data and analytics to keep the world moving. Delivering insight, built from decades of experience in the sector, enabling travel companies, aircraft manufacturers, airports, airlines and financial institutions, among others, to make logical and informed decisions which shape the future of travel, growing revenues and enhancing customer experiences. Cirium is part of RELX, a global provider of information-based analytics and decision tools for professional and business customers. The shares of RELX PLC are traded on the London, Amsterdam and New York Stock Exchanges using the following ticker symbols: London: REL; Amsterdam: REN; New York: RELX.
For further information please follow Cirium updates on LinkedIn or Twitter or visit www.cirium.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230124005195/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 13:30:00 CEST | Press release
If approved, Opzelura® (ruxolitinib) cream will be the first steroid-free, topical JAK treatment option in the European Union (EU) for adults with moderate atopic dermatitis (AD) for whom standard topical therapies have failedAD, the most common type of eczema which affects 230 million people globally,1 is a chronic, recurring, inflammatory and highly pruritic (itchy) skin condition that can have a significant impact on daily life2Phase 3 TRuE‑AD4 data supporting the positive CHMP opinion demonstrated that ruxolitinib cream met both co‑primary endpoints at Week 8, maintained disease control with as-needed treatment through Week 24 and was well tolerated3,4,5 Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids
Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 13:00:00 CEST | Press release
Recommendation based on TROPION-Breast02 phase 3 trial where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival If approved, Datroway has potential to be the first TROP2 directed antibody drug conjugate for patients in EU with a demonstrated overall survival benefit as first-line treatment Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use
DAYBU®(trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 12:49:00 CEST | Press release
-- European Commission decision expected in the coming months-- If approved, DAYBU®would become the first treatment for neurobehavioral symptoms of Rett syndrome in the European Union Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating
HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 11:18:00 CEST | Press release
HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi
Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 10:28:00 CEST | Press release
Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
